The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site.

All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Taiwan’s capital markets malaise

A falling number of corporates are choosing to list on the Taiwan Stock Exchange. Given the dire after-market performance of Aslan Pharmaceuticals, it is not hard to see why.

taipei cityscape clouds-600
Taipei is not the place you go to complete big equity capital markets transactions,
wherever you come from

When Aslan Pharmaceuticals cast around for the right place to sell shares earlier this year, it did not choose Hong Kong, nor its hometown of Singapore, nor even mainland China’s two leading bourses, but Taiwan.

Aslan’s chief executive Carl Firth, a former head of Asia healthcare investment banking at Bank of America Merrill Lynch, was convinced it was the right decision. The firm’s lack of profitability – it posted a small pre-tax loss in 2016 – had ruled out Hong Kong, while the US exchanges were deemed too volatile. Singapore was also nixed, due to the lack of biotech firms listed in the Lion City. 

Taiwan, however, was a different matter. The Taiwan Stock Exchange (TSE) was widely viewed as a sleepy little bourse lacking the liquidity and trading volumes of Shanghai or Hong Kong. But it had its upsides. 

The island boasts one of the world’s best-run and most-generously funded public healthcare systems.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.

SUBSCRIBE ONLINE TODAY

Unlimited access to Euromoney.com and Asiamoney.com

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually

FREE 7 DAY TRIAL

Unlimited access to Euromoney.com and Asiamoney.com, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors

LOGIN NOW

Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree